相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL
Georgia Greaves et al.
CELL DEATH AND DIFFERENTIATION (2019)
RNA Splicing and Disease: Animal Models to Therapies
Matias Montes et al.
TRENDS IN GENETICS (2019)
Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators
Daniel Aird et al.
NATURE COMMUNICATIONS (2019)
Targeting splicing abnormalities in cancer
Anant A. Agrawal et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2018)
Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability
Kenichi Iwai et al.
EMBO MOLECULAR MEDICINE (2018)
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
Michael Seiler et al.
NATURE MEDICINE (2018)
Dual modulation of MCL-1 and mTOR determines the response to sunitinib
Mohamed Elgendy et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Global analysis of pre-mRNA subcellular localization following splicing inhibition by spliceostatin A
Rei Yoshimoto et al.
RNA (2017)
CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor
Tyler Funnell et al.
NATURE COMMUNICATIONS (2017)
Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex
Teng Teng et al.
NATURE COMMUNICATIONS (2017)
The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mc1-1
M. Larrayoz et al.
LEUKEMIA (2016)
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
A. Sveen et al.
ONCOGENE (2016)
Therapeutic targeting of splicing in cancer
Stanley Chun-Wei Lee et al.
NATURE MEDICINE (2016)
An extensive program of periodic alternative splicing linked to cell cycle progression
Daniel Dominguez et al.
ELIFE (2016)
CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer
Taku Yoshida et al.
CANCER RESEARCH (2015)
First Evidence That Oligopyridines, α-Helix Foldamers, Inhibit Mcl-1 and Sensitize Ovarian Carcinoma Cells to Bcl-xL-Targeting Strategies
Celine Gloaguen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation
Junghui Koo et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
Inhibitors of CLK Protein Kinases Suppress Cell Growth and Induce Apoptosis by Modulating Pre-mRNA Splicing
Shinsuke Araki et al.
PLOS ONE (2015)
Analysis of drug combinations: current methodological landscape
Julie Foucquier et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Alternative splicing: a pivotal step between eukaryotic transcription and translation
Alberto R. Kornblihtt et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Misregulation of Pre-mRNA Alternative Splicing in Cancer
Jian Zhang et al.
CANCER DISCOVERY (2013)
Regulation of Mcl-1 by SRSF1 and SRSF5 in Cancer Cells
Hannah L. Gautrey et al.
PLOS ONE (2012)
Inhibition of MCL-1 enhances Lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy
Aditi Pandya Martin et al.
CANCER BIOLOGY & THERAPY (2010)
An Alternative Splicing Network Links Cell-Cycle Control to Apoptosis
Michael J. Moore et al.
CELL (2010)
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged
Charles J. David et al.
GENES & DEVELOPMENT (2010)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Alternative isoform regulation in human tissue transcriptomes
Eric T. Wang et al.
NATURE (2008)
Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis
AM Petros et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss
B Modrek et al.
NATURE GENETICS (2003)
分享论文
